AbCellera grabs USD 105 Million for series B funding round; Gilead inks USD 2 Billion deal with Arcus; GlaxoSmithKline’s anti-BCMA antibody receives a boost; The startup focuses on glioblastoma tumors with CAR-T therapy; For more information visit: https://www.delveinsight.com/blog/recent-pharma-happenings-for-abcellera-gilead-glaxosmithkline-arcus/